BRENNEN

Industries / Health / Healthcare / Medical spas

Injections

This is the work of injecting products into the face: botulinum toxins that relax the muscles that crease the skin, and fillers that add volume or prompt the body to make its own collagen.

7

Milestones achieved, from 1981 to 2013.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 1981

    Collagen from cows

    The US Food and Drug Administration (FDA) approved Zyderm Collagen Implant, purified collagen from cattle, on 22 July 1981. A 2023 review calls it the first collagen filler and says it remained the only FDA-approved injectable filler until 2003. About 2–4% of people are allergic to bovine collagen, so two negative skin tests were needed before treatment. Zyderm's approval was withdrawn on 25 October 2011.

    LessonThe review notes that the risk of immune and allergic reactions soon reduced the popularity of animal-derived collagen fillers.

    pmc.ncbi.nlm.nih.govaccessdata.fda.gov

    Credit

    Inamed Corporation, as named in the review; the FDA record now lists Allergan

  2. 1992

    Toxin smooths frown lines

    Botulinum toxin type A blocks the signal from nerve to muscle, so the injected muscle relaxes for some months. Alan Scott had published its use from 1980 to weaken eye muscles in place of surgery for strabismus, a squint. Jean Carruthers, of the University of British Columbia's ophthalmology department in Vancouver, and Alastair Carruthers injected it into the frown muscles between the brows of 18 patients; 16 of the 17 they followed improved for 3 to 11 months, with minimal side effects.

    ebi.ac.uk

    Credit

    Jean and Alastair Carruthers

  3. 2002

    Wrinkle toxin licensed

    On 12 April 2002 the FDA approved Allergan's botulinum toxin type A, sold as BOTOX COSMETIC, for the temporary improvement of moderate to severe frown lines between the brows in adults under 65, in vials of 100 units. Until then the same drug was licensed only for eye-muscle and neck-muscle disorders.

    accessdata.fda.gov

    Credit

    Allergan; FDA Center for Biologics Evaluation and Research

  4. 2003

    A gel not from animals

    Hyaluronic acid is a sugar chain that holds water in skin. On 12 December 2003 the FDA approved Restylane, a gel of hyaluronic acid from Q-Med of Uppsala, Sweden, for injection into the skin to correct moderate to severe wrinkles and folds. A 2024 review credits Restylane with introducing non-animal stabilized hyaluronic acid, made without animal tissue; most hyaluronic acid for fillers is now made by bacterial fermentation. FDA records list more than 15 further dermal filler approvals since, among them Juvéderm in 2006, Belotero Balance in 2011 and Teoxane's RHA fillers in 2017.

    api.fda.govpmc.ncbi.nlm.nih.gov

    Credit

    Q-Med AB

  5. 2004

    Fillers that build collagen

    Some fillers work slowly, by provoking the body to lay down new collagen around injected particles. The FDA approved Sculptra, microspheres of poly-L-lactic acid, a plastic the body breaks down, on 3 August 2004 for facial fat loss in people with HIV; an aesthetic version for folds and wrinkles followed in 2009. Radiesse, microspheres of calcium hydroxylapatite, the mineral of bone, followed on 22 December 2006.

    pmc.ncbi.nlm.nih.govapi.fda.govapi.fda.gov

    Credit

    Q-Med AB (Sculptra); Merz North America, the applicant in the FDA record (Radiesse)

  6. 2009

    Units that do not convert

    On 29 April 2009 the FDA approved Dysport, Ipsen's botulinum toxin, the second for frown lines in the US. The labels now gave each product its own name, onabotulinumtoxinA for Botox and abobotulinumtoxinA for Dysport, and the Botox Cosmetic label of July 2009 states that its units "are not interchangeable with other preparations of botulinum toxin products" and cannot be converted into another product's units.

    LessonA dose written in units means nothing without the product's name.

    accessdata.fda.govaccessdata.fda.gov

    Credit

    FDA; Ipsen Biopharm; Allergan

  7. 2013

    Filler for the cheeks

    On 22 October 2013 the FDA approved Allergan's Juvéderm Voluma XC for deep injection, under the skin or onto the bone, to augment the cheeks and correct age-related volume loss in the midface of adults over 21. The US filler approvals before it were mostly for lines and folds.

    api.fda.gov

    Credit

    Allergan

Watch for

  1. A toxin working within hours

    AbbVie's trenibotulinumtoxinE is a botulinum toxin of serotype E, which AbbVie calls the first of its kind; the toxins approved for wrinkles so far are all type A. AbbVie says it acts as early as 8 hours after injection and lasts 2 to 3 weeks, so a new patient can try the look before a longer-lasting toxin, with data from more than 2,100 patients. The FDA answered the April 2025 application with a complete response letter, a refusal pending fixes, in April 2026; the company says the letter concerned manufacturing only.

    Achieved whenthe FDA or another major regulator licenses it and an outside group reports the onset and duration.

    news.abbvie.comdermatologytimes.com

    Claimed by

    AbbVie, April 2025 and April 2026

  2. Toxin sold ready to inject

    Other toxins come as a powder that the clinic dissolves before use. Galderma's relabotulinumtoxinA (Relfydess) comes as a liquid. Galderma says it acts as early as day 1 and lasts six months for frown lines and crow's feet, and that it is approved in more than 20 markets, including the EU, the UK and Australia. The FDA accepted a resubmitted application in February 2026 after an earlier refusal over manufacturing; openFDA listed no US approval on 19 November 2026.

    Achieved whenthe FDA licenses it and an independent trial compares its duration with a powder toxin.

    biospace.com

    Claimed by

    Galderma, February 2026

Open

  1. 01

    Ask the label, twenty times

    A public set of about 300 questions whose answers are printed in the official labels of the toxins and fillers sold in the US and Europe: units per vial, dilution, storage, approved areas and doses, who should not be treated, and whether units convert between brands (they do not). Each AI model that clinics might use as an assistant is asked every question 20 times, and a question counts as passed only if all 20 answers are right. Nothing is injected and no drug is handled.

    The brief
    Credit · unclaimed
  2. 02

    An open table of fillers

    A public table of the measured properties of hyaluronic acid fillers: how stiff the gel is (G′, the elastic modulus, in pascals), how it flows (G″ and tan δ), how well it holds together (cohesivity), its hyaluronic acid concentration and how it is cross-linked, with the test frequency, temperature and method recorded for every value so that like is compared with like. Values come from published papers, regulators' summaries and makers' documents, and disagreements between sources are flagged.

    The brief
    Credit · unclaimed

Open 01 · the brief

Ask the label, twenty times

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public set of about 300 questions whose answers are printed in the official labels of the toxins and fillers sold in the US and Europe: units per vial, dilution, storage, approved areas and doses, who should not be treated, and whether units convert between brands (they do not). Each AI model that clinics might use as an assistant is asked every question 20 times, and a question counts as passed only if all 20 answers are right. Nothing is injected and no drug is handled.

Why it is still open

Published tests score chatbots by expert opinion. Radulesco and colleagues (Aesthetic Plastic Surgery, 2025) had two surgeons rate six chatbots' injection plans for 40 patients on a five-point scale and concluded that safety limits rule out unsupervised use; their questions are tied to patients, not to a public answer key. No public question set tied line by line to product labels, with repeated runs, was found.

orbi.umons.ac.be

Built with what exists

Label PDFs from the FDA's Drugs@FDA and device approval databases and the EU summaries of product characteristics; a Python harness that sends each question and checks the answer against the label line; open-weight models such as Mistral Large 4 run on the tester's own machine (Notes: "A trillion open parameters") alongside hosted models; the pass-on-all-20 bar used in Microsoft's ThinkingBox research (Notes: "All twenty times").

  1. First step

    Write 30 questions from the Botox Cosmetic and Dysport labels, half of them about units, and run one model 20 times on each.

  2. Done looks like

    300 questions, each linked to the label sentence that answers it and checked by two licensed injectors or pharmacists; at least five models run 20 times each; a public table of all-20 pass rates per model, with every wrong unit conversion listed.

Open 02 · the brief

An open table of fillers

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table of the measured properties of hyaluronic acid fillers: how stiff the gel is (G′, the elastic modulus, in pascals), how it flows (G″ and tan δ), how well it holds together (cohesivity), its hyaluronic acid concentration and how it is cross-linked, with the test frequency, temperature and method recorded for every value so that like is compared with like. Values come from published papers, regulators' summaries and makers' documents, and disagreements between sources are flagged.

Why it is still open

The largest single-method comparison, published in Facial Plastic Surgery in 2022, was written by Allergan Aesthetics staff and uses data on file at Allergan. A 2024 Korean study notes that there is no standardized test of cohesion, and found that rheology results did not reflect cohesion. No open, cross-source table was found.

pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov

Built with what exists

The FDA's device approval database and its summaries of safety and effectiveness; open-access papers through Europe PMC; PDF table extraction with pdfplumber; a public spreadsheet or Datasette site.

  1. First step

    Extract the tables from the 2022 Allergan paper and the 2024 Korean study into one sheet with a column for test conditions.

  2. Done looks like

    At least 60 products from at least eight makers, each value linked to its source and test conditions, and a list of every product where two sources disagree by more than 20%.